Our study provides insights into the specific delivery of hAFSC-EVs into inflammatory macrophages and sheds light on the potential therapeutic applications of these EVs for regulating inflammatory macrophage phenotypes.

3 months ago

Journal

CD44 (CD44 Molecule)

4ms

Baicalin-loaded micelles: Modulating M1 macrophages to overcome Lenvatinib resistance in anaplastic thyroid carcinoma. (PubMed, Int Immunopharmacol)

Notably, in vivo experiments illustrated the efficacy of baicalin-PMs in suppressing M1 macrophage polarization and restraining tumor growth in the context of Lenvatinib resistance in ATC. Overall, the comprehensive multi-omics analysis underlines the potential of baicalin-PMs in reversing Lenvatinib resistance by modulating M1 macrophage function and inhibiting the MET factor, thus offering a novel strategy and target for combatting ATC resistance to Lenvatinib.

4 months ago

Journal

MET (MET proto-oncogene, receptor tyrosine kinase)

Lenvima (lenvatinib)

4ms

MICA+ Tumor Cells Modulate Macrophage Phenotype and Function via PPAR/EHHADH-Mediated Fatty Acid Metabolism in Hepatocellular Carcinoma (HCC). (PubMed, Cancers (Basel))

The underlying metabolic and molecular mechanisms revealed that MICA in tumor cells induced M2-like polarization through the PPAR/EHHADH pathway, which regulates the fatty acid oxidation (FAO) in macrophages. The metabolic gene EHHADH, which is associated with MICA, led to alterations in M2-like macrophages by promoting heightened fatty acid uptake and augmenting levels of FAO within macrophages.

4 months ago

Journal

MICA (MHC Class I Polypeptide-Related Sequence A)

4ms

Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov)

P2, N=27, Not yet recruiting, Abramson Cancer Center at Penn Medicine

4 months ago

New P2 trial

Keytruda (pembrolizumab) • Imprime PGG (odetiglucan)

5ms

Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia (clinicaltrials.gov)

P1/2, N=12, Completed, SDK Therapeutics, Inc. | Recruiting --> Completed

5 months ago

Trial completion

5ms

Multimerin-1 modulates macrophage M2 polarization and enhances tumor cell stemness in glioblastoma. (PubMed, Neurol Res)

MMRN1 is a critical BTSC-related biomarker that contributes to GBM progression by enhancing tumor stemness and modulating the immune microenvironment. Targeting MMRN1 May represent a promising therapeutic approach for GBM treatment.

5 months ago

Journal

TLR7 (Toll Like Receptor 7) • IRF5 (Interferon Regulatory Factor 5)

6ms

Phenethyl isothiocyanate modulates macrophage migration inhibitory factor and suppresses malignant phenotypes of glioblastoma cells. (PubMed, Food Funct)

Our findings revealed that PEITC significantly reduced MIF expression in GL-261 cells, both in culture and in orthotopic tumor tissue, and decreased MIF-induced cellular signaling. These results suggest that PEITC has potential to be a therapeutic agent for glioblastoma by inhibiting tumor growth and modulating the immune response through MIF suppression.

6 months ago

Journal

MIF (Macrophage Migration Inhibitory Factor)

6ms

Oral-ATO for TP53-mutated Myeloid Malignancies (clinicaltrials.gov)

P2, N=30, Recruiting, The University of Hong Kong | Not yet recruiting --> Recruiting

6 months ago

Enrollment open

Venclexta (venetoclax) • azacitidine

9ms

Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma (clinicaltrials.gov)

P1/2, N=32, Completed, HiberCell, Inc. | Phase classification: P1b --> P1/2 | N=48 --> 32

9 months ago

Phase classification • Enrollment change

Erbitux (cetuximab) • 5-fluorouracil • irinotecan • Imprime PGG (odetiglucan)